Capricor Therapeutics Receives FDA Complete Response Letter for Deramiocel
FDA issues CRL for Capricor's deramiocel BLA, citing insufficient effectiveness data despite two positive RCTs in Duchenne muscular dystrophy.


The FDA's rejection of Capricor Therapeutics' resubmitted BLA for deramiocel sharpens a long-standing tension in rare disease drug development: whether two positive randomized controlled trials are sufficient to meet the agency's substantial evidence of effectiveness standard when patient populations are small and enrollment is inherently constrained. The Complete Response Letter (CRL), issued for the allogeneic cell therapy targeting Duchenne muscular dystrophy (DMD), cites insufficient effectiveness data alongside unspecified clinical deficiencies.
Capricor's clinical program rested on two randomized, double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, both of which the company reports met their primary endpoints. For regulatory affairs teams managing BLAs under accelerated approval or RMAT designation pathways, the agency's position here signals that endpoint achievement alone may not resolve evidentiary gaps when the underlying dataset is limited by rare-disease enrollment realities. Deramiocel holds RMAT, Orphan Drug, and Rare Pediatric Disease designations in the U.S., designations that facilitate engagement but do not lower the statutory approval bar.
The mechanistic profile of deramiocel adds a layer of regulatory complexity. The therapy consists of allogeneic cardiosphere-derived cells (CDCs) that act through exosome-mediated immunomodulation, shifting macrophage phenotype toward an anti-inflammatory, pro-healing state to preserve skeletal and cardiac muscle function. Characterizing that mechanism of action to FDA's satisfaction under 21 CFR Part 601 biologics standards, particularly for a cell-derived product with indirect effector activity, presents a distinct analytical challenge compared with small-molecule or monoclonal antibody submissions.
DMD affects approximately 15,000 individuals in the United States, predominantly males, with cardiomyopathy and heart failure representing the primary cause of mortality. The absence of curative options and the progressive, fatal course of the disease have historically supported regulatory flexibility; the CRL suggests that flexibility has limits when clinical data packages are contested on effectiveness grounds.
Capricor reported cash and marketable securities of approximately $198.5 million as of September 30, 2026, which the company states is sufficient to fund planned operations for at least 12 months, with a review of operating costs underway to extend that runway. The company is evaluating the CRL and has not yet announced whether it will pursue a Type A meeting with FDA, submit additional data, or seek an alternative regulatory pathway.
The outcome of Capricor's post-CRL engagement with FDA will serve as a reference point for sponsors navigating the evidentiary threshold for cell and gene therapies in rare pediatric indications under the current review framework.
Source: Capricor Therapeutics, Inc. via GlobeNewswire, November 20, 2026. Conference call and webcast scheduled for Monday, November 23, 2026, at 8:30 a.m. ET; dial-in 1-800-717-1738 (domestic), conference ID 27699.

Reporting on the science, business and regulation shaping the pharmaceutical industry.
More from Pharma News
All stories →
India Positions Itself as Global Diabetes R&D Hub Targeting GLP-1 and Microbiome Therapies

Greenwich Rx Recalls Compounded Sterile Products Nationwide

Discussion